DCT

2:26-cv-07798

Aragon Pharma Inc v. MSN Pharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Aragon Pharmaceuticals, Inc. v. MSN Pharmaceuticals Inc., 2:26-cv-07798, D.N.J., 06/26/2026
  • Venue Allegations: Venue is based on Defendant MSN Pharmaceuticals Inc. having a regular and established place of business in the District of New Jersey, and Defendant Novadoz Pharmaceuticals, LLC residing in New Jersey.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of the prostate cancer drug Erleada® (apalutamide) infringes four U.S. patents covering crystalline forms, formulations, and methods of using the drug.
  • Technical Context: The technology concerns apalutamide, a second-generation anti-androgen, used for treating specific types of prostate cancer, a major cause of cancer-related death in men.
  • Key Procedural History: This action was filed under the Hatch-Waxman Act, prompted by Defendants' submission of ANDA No. 221599 to the FDA, which included a Paragraph IV certification asserting that Plaintiffs' patents are invalid, unenforceable, or not infringed. The complaint notes that Defendants have previously consented to jurisdiction in the District of New Jersey in other patent litigations.

Case Timeline

Date Event
2012-06-07 '663 Patent Priority Date
2014-12-05 '493 Patent Priority Date
2016-11-01 U.S. Patent No. 9,481,663 Issued
2019-01-30 '952 and '497 Patents Priority Date
2024-04-23 U.S. Patent No. 11,963,952 Issued
2025-05-20 U.S. Patent No. 12,303,493 Issued
2025-05-20 U.S. Patent No. 12,303,497 Issued
c. March 2026 Defendants allegedly submitted ANDA No. 221599 to FDA
2026-05-19 Defendants sent Paragraph IV Notice Letter to Plaintiffs
2026-05-28 Defendants produced certain ANDA-related documents to Plaintiffs
2026-06-26 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,481,663 - "Crystalline Forms of an Androgen Receptor Modulator"

  • Patent Identification: U.S. Patent No. 9,481,663, "Crystalline Forms of an Androgen Receptor Modulator," issued November 1, 2016.

The Invention Explained

  • Problem Addressed: The patent addresses the need for effective androgen receptor (AR) modulators for the treatment of prostate cancer US9481663B2, col. 5:5-10 Developing a drug substance with consistent physical properties, such as a stable crystalline form, is a critical challenge in pharmaceutical development.
  • The Patented Solution: The patent discloses specific crystalline forms (polymorphs) of the apalutamide molecule US 9,481,663, col. 2:1-4 The invention specifically claims "Form B," a distinct crystalline structure identified by its unique X-ray powder diffraction (XRPD) pattern, as illustrated in the patent's figures US 9,481,663, FIG. 2 US 9,481,663, col. 9:4-24 This specific form provides a stable and reproducible solid state for the active pharmaceutical ingredient.
  • Technical Importance: A defined, stable crystalline form is crucial for ensuring consistent manufacturing, bioavailability, and shelf-life of a pharmaceutical product.

Key Claims at a Glance

  • The complaint asserts independent claims 1 and 17, as well as dependent claim 13 Compl. ¶72
  • Independent Claim 1 (Composition of Matter):
    • Crystalline Form B of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide
    • Characterized as having an X-ray powder diffraction (XRPD) pattern with characteristic peaks at specific 2-Theta angles (12.1±0.1°, 16.0±0.1°, 16.7±0.1°, 20.1±0.1°, 20.3±0.1°).
  • Independent Claim 17 (Method of Treatment):
    • A method of treating prostate cancer in a mammal
    • Comprising administering a pharmaceutical composition
    • Wherein the composition comprises apalutamide which comprises the crystalline Form B as defined by its characteristic XRPD pattern.

U.S. Patent No. 11,963,952 - "Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer"

  • Patent Identification: U.S. Patent No. 11,963,952, "Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer," issued April 23, 2024.

The Invention Explained

  • Problem Addressed: The patent describes the need for improved treatment options for patients with metastatic castration-sensitive prostate cancer (mCSPC), as existing therapies like androgen deprivation therapy (ADT) have limitations US11963952B2, col. 1:41-57 A key challenge in cancer therapy is managing treatment-related toxicity to maintain patient quality of life and adherence to therapy.
  • The Patented Solution: The patent claims a specific method for managing toxicity when treating mCSPC with apalutamide US 11,963,952, abstract The invention is a dosing regimen where the daily dose of apalutamide is reduced from a standard dose to 180 mg or 120 mg if the patient experiences a toxicity level of Grade 3 or higher US 11,963,952, col. 3:1-5
  • Technical Importance: Standardizing dose-modification protocols based on specific toxicity grades provides physicians with a clear, evidence-based pathway to manage adverse effects, potentially improving patient safety and enabling continued treatment.

Key Claims at a Glance

  • The complaint asserts claims 6, 7, and 8, which depend from independent claim 1 Compl. ¶92
  • Independent Claim 1:
    • A method for treating mCSPC in a male human, consisting essentially of:
    • Administering a therapeutically effective amount of an anti-androgen.
    • Wherein the dosage of the anti-androgen is decreased if the patient experiences a greater than or equal to Grade 3 toxicity.
  • The asserted dependent claims further specify that the anti-androgen is apalutamide (claim 6) and that the decreased dosage is 180 mg per day (claim 7) or 120 mg per day (claim 8) Compl. ¶92

U.S. Patent No. 12,303,493 - "Anticancer Compositions"

  • Patent Identification: U.S. Patent No. 12,303,493, "Anticancer Compositions," issued May 20, 2025 Compl. ¶60
  • Technology Synopsis: The patent describes a pharmaceutical formulation for apalutamide (referred to as ARN-509) US12303493B2, col. 1:20-35 The invention is a "solid dispersion" comprising apalutamide and a polymer, hydroxypropyl methylcellulose acetate succinate (HPMCAS), designed to provide improved stability and a reduced pill burden for patients US 12,303,493, col. 1:45-54
  • Asserted Claims: Independent claims 1 and 16 are asserted Compl. ¶106
  • Accused Features: Defendants' proposed 60 mg and 240 mg generic apalutamide tablets are alleged to be pharmaceutical formulations comprising a solid dispersion of apalutamide and HPMCAS Compl. ¶¶108-110

U.S. Patent No. 12,303,497 - "Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer"

  • Patent Identification: U.S. Patent No. 12,303,497, "Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer," issued May 20, 2025 Compl. ¶61
  • Technology Synopsis: The patent claims a method of treating mCSPC by administering apalutamide in combination with androgen deprivation therapy (ADT) US12303497B2, claim 1 The invention is based on clinical trial results demonstrating that this treatment regimen provides a statistically significant increase in overall survival and progression-free survival compared to treatment with a placebo plus ADT, including specific quantitative outcomes like a 33% reduction in risk of death US 12,303,497, claim 12
  • Asserted Claims: Independent claims 1 and 12 are asserted Compl. ¶124
  • Accused Features: The use of Defendants' proposed generic apalutamide products is alleged to infringe because physicians and patients will practice the claimed method to achieve the specified survival benefits, as will be instructed by the product's label Compl. ¶125

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Defendants' "Proposed ANDA Products," identified as generic apalutamide tablets in 60 mg and 240 mg strengths, for which Defendants seek FDA approval via ANDA No. 221599 Compl. ¶2 Compl. ¶64

Functionality and Market Context

  • The Proposed ANDA Products contain the active pharmaceutical ingredient apalutamide, which is an androgen receptor inhibitor indicated for the treatment of mCSPC and non-metastatic castration-resistant prostate cancer Compl. ¶56 The complaint alleges Defendants seek to market these products as generic equivalents to Plaintiffs' brand-name drug, Erleada®, prior to the expiration of the patents-in-suit Compl. ¶2 The complaint includes the chemical structure of apalutamide, identifying it as the core component of the accused products Compl. ¶108

IV. Analysis of Infringement Allegations

U.S. Patent No. 9,481,663 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
Crystalline Form B of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide The Proposed ANDA Products allegedly "contain some amount of crystalline Form B of apalutamide." ¶73 col. 9:4-9
that is characterized as having... an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 12.1±0.1° 2-Theta, 16.0±0.1° 2-Theta, 16.7±0.1° 2-Theta, 20.1±0.1° 2-Theta, 20.3±0.1° 2-Theta. The crystalline Form B in the Proposed ANDA Products is allegedly "characterized as having... an X-ray powder diffraction (XRPD) pattern with characteristic peaks at" the angles specified in the claim. ¶74 col. 10:1-8
  • Identified Points of Contention:
    • Technical Question: The central dispute for the '663 patent will be factual: does the apalutamide in Defendants' proposed generic product exist in "crystalline Form B" as defined by the patent? This will likely involve a "battle of the experts" analyzing competing XRPD and other characterization data from the accused products.
    • Scope Question: The claim language requires a pattern "substantially the same as" the one in FIG. 2 of the patent (as alleged in Compl. ¶74). The litigation may focus on the proper construction of "substantially," questioning how much variation in XRPD peak position and intensity is permissible before a product falls outside the claim's scope.

U.S. Patent No. 11,963,952 Infringement Allegations

Claim Element (from Independent Claim 1 and Dependent Claims 6-8) Alleged Infringing Functionality Complaint Citation Patent Citation
a method of treating metastatic castration-sensitive prostate cancer in a male human, said method consisting essentially of administering a therapeutically effective amount of... apalutamide The complaint alleges that physicians and patients will practice the claimed method by using the Proposed ANDA Products to treat mCSPC. ¶92 col. 3:6-10
wherein its dosage is decreased to 180 mg per day or 120 mg per day if the male human experiences a greater than or equal to Grade 3 toxicity. The use of the Proposed ANDA Products will allegedly involve practicing the specific dose reduction regimen in response to Grade 3 toxicity, as will be directed by the product's labeling. ¶92 col. 3:1-5
  • Identified Points of Contention:
    • Legal Question (Inducement): Infringement of this method claim hinges on a theory of induced infringement. The key question for the court will be whether Defendants' product labeling, by instructing physicians to reduce the dose to 180 mg or 120 mg in response to Grade 3 toxicity, demonstrates the specific intent required to establish inducement under 35 U.S.C. § 271(b).
    • Scope Question: The claim uses the transitional phrase "consisting essentially of." This raises the question of whether other treatment steps a physician might take concurrently (e.g., administering anti-nausea medication) would be considered to materially affect the basic and novel characteristics of the claimed dose-reduction method, thereby potentially taking the physician's actions outside the scope of the claim.

V. Key Claim Terms for Construction

For U.S. Patent No. 9,481,663

  • The Term: "substantially the same as"
  • Context and Importance: This term, used to describe the required XRPD pattern in claim 1, is critical for determining the scope of the composition claim. The outcome of the infringement analysis will likely depend on whether the XRPD pattern of the defendants' product is deemed "substantially the same as" the pattern shown in the patent's FIG. 2.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent does not appear to provide an explicit definition of "substantially the same," which may support an argument for its plain and ordinary meaning, allowing for some degree of variation inherent in XRPD measurements between different machines and samples.
    • Evidence for a Narrower Interpretation: The explicit listing of five distinct peaks with a tight tolerance of ±0.1° 2-Theta in the claim itself could be used to argue for a narrow interpretation, suggesting that a matching pattern must contain all listed peaks within those precise ranges US 9,481,663, col. 10:1-8

For U.S. Patent No. 11,963,952

  • The Term: "consisting essentially of"
  • Context and Importance: This transitional phrase in claim 1 governs the scope of the claimed method. Practitioners may focus on this term because its construction will determine whether the administration of other supportive-care drugs alongside the claimed apalutamide dose reduction would constitute an additional, material step that places the activity outside the scope of the claim.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification explicitly defines the phrase as limiting the claim to the specified steps "and those that do not materially affect the basic and novel characteristic(s)" of the invention US 11,963,952, col. 6:5-9 This language could be used to argue that concomitant therapies that manage side effects without altering the fundamental dose-reduction protocol are permitted within the claim's scope.
    • Evidence for a Narrower Interpretation: A defendant may argue that the "basic and novel characteristic" is the specific act of dose reduction in isolation, and that any additional therapeutic step, such as administering a separate drug to manage a different side effect, materially alters the method and thus falls outside the claim.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for all four patents-in-suit (Compl. ¶77; Compl. ¶78; Compl. ¶79; Compl. ¶80; Compl. ¶81; Compl. ¶82; Compl. ¶83; Compl. ¶84; Compl. ¶85; Compl. ¶86; Compl. ¶87). The primary basis for inducement is the allegation that Defendants' product labels will instruct physicians and patients to use the generic tablets in an infringing manner (e.g., by following the patented dosing regimens). The basis for contributory infringement includes the allegation that the Proposed ANDA Products are not staple articles of commerce suitable for substantial non-infringing use (Compl. ¶¶78; ¶94; ¶111; ¶127).
  • Willful Infringement: The complaint does not use the term "willful infringement" but alleges facts that could support such a claim. It asserts that Defendants have "actual knowledge" of the patents-in-suit, at least as of receiving the May 19, 2026 Notice Letter, and that their infringement is therefore knowing and intentional (Compl. ¶¶80; ¶96; ¶113; ¶129). The prayer for relief requests a declaration that this is an "exceptional case" under 35 U.S.C. § 285, which is often associated with findings of willful infringement Compl. Prayer for Relief ¶F

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of scientific characterization: For the patents on crystalline forms and formulations ('663 and '493 patents), the case will likely turn on a factual dispute resolved by competing expert testimony. Can Plaintiffs prove, by a preponderance of the evidence, that Defendants' proposed generic products contain the specific "crystalline Form B" or "solid dispersion" structures as claimed in the patents?
  • A second key question will be one of legal interpretation regarding inducement: For the method-of-use patents ('952 and '497 patents), a central issue will be whether Defendants' act of seeking approval for a generic product with a label that necessarily mirrors the brand-name label-and thus instructs the patented methods-demonstrates the specific intent required for a finding of induced infringement.
  • A third question will be one of validity: While the complaint focuses on infringement, Defendants have served a Paragraph IV certification alleging the patents are invalid and/or unenforceable Compl. ¶66 The ultimate resolution of the case will depend not only on the infringement analysis but also on whether the patents-in-suit can withstand Defendants' inevitable challenges to their validity.
Loading Complaint